Zoetis Inc. (NYSE:ZTS) Shares Purchased by Atomi Financial Group Inc.

Atomi Financial Group Inc. raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 16.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,025 shares of the company’s stock after purchasing an additional 839 shares during the quarter. Atomi Financial Group Inc.’s holdings in Zoetis were worth $1,177,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Webster Bank N. A. grew its stake in Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after purchasing an additional 82 shares in the last quarter. Quarry LP grew its stake in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in Zoetis during the 4th quarter valued at approximately $40,000. LRI Investments LLC bought a new position in Zoetis during the 1st quarter worth approximately $43,000. Finally, Hazlett Burt & Watson Inc. lifted its holdings in Zoetis by 60.7% during the 1st quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after buying an additional 102 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 0.0 %

Shares of Zoetis stock opened at $187.37 on Wednesday. The business’s fifty day moving average price is $187.41 and its two-hundred day moving average price is $175.64. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The company has a market capitalization of $84.89 billion, a P/E ratio of 36.10, a PEG ratio of 2.91 and a beta of 0.89. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.41 EPS. As a group, research analysts forecast that Zoetis Inc. will post 5.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Stifel Nicolaus increased their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Piper Sandler increased their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, BTIG Research increased their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $220.38.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.